International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…

👉👉 Happy to share results of investigator initiated trial of Ruxolitinib in Ph-Like ALL. We did not see any significant responses in R/R adult Ph-like B-ALL with ruxolitinib. 👉Looking back at my emails Marina Konopleva and I had initial discussions with Incyte for this trial at ASH

Impressive results of 7+3 + Ziftomenib in newly diagnosed AML patients with NPM1m or KMT2Ar presented by Harry Erba. We are embarking on a new era of menin inhibitors in combination with frontline therapy in newly Dx AML w/ NPM1m or KMT2Ar. European Hematology Association #EHA25

🔥 Breakthrough in extensive-stage small-cell lung cancer maintenance! 🫁Lurbinectedin + Atezolizumab doubled PFS vs Atezolizumab alone! 🫁OS benefit also significant (13.2 vs 10.6 mo) 💥 First phase 3 trial to improve both PFS & OS in 1L maintenance for ES-SCLC. OncoAlert

📢 Just out in Cancer Treatment Reviews! We explore a key challenge in HR+/HER2– BC: resistance to CDK4/6i. 💡 Why it happens 🔄 How to overcome it with combos 🚀 What’s next Proud of the great collaborative effort behind this work. 📖 doi.org/10.1016/j.ctrv…

Presented at #EHA2025: Among patients with chronic lymphocytic leukemia, undetectable MRD and progression-free survival were more common with ibrutinib–venetoclax than with ibrutinib alone or chemoimmunotherapy, with benefits sustained at 5 years. Full FLAIR phase 3 trial

Out now in Journal of Clinical Oncology Closing the Gap: PTCy Boosts Survival After Mismatched Stem Cell Transplants Summary: In a multicenter phase II trial, post-transplant cyclophosphamide (PTCy)-based GVHD prophylaxis enabled strong 1-year survival outcomes in patients receiving peripheral

Great session by Prof.Nitin Jain sir on ALL advances at AIIMS,ND. Always grateful to Ranjit Kumar Sahoo sir

Study that went under the radar at ASCO. WBRT with hippocampal sparing and memantine versus SRS for 5-20 brain metastases. Same Overall survival, Lower Symptom Burden and Life Interference with SRS, Better KPS with SRS. New standard of care! Congrats Dr. Aizer on this amazing

Nitin Jain AIIMS, New Delhi 🇮🇳 Deepam Pushpam Prashant Mehta Manju Sengar Anirban Maitra Naveen Pemmaraju, MD Here is a photograph!

A no. of trials in RR DLBCL with RGemOx as comparator all show: • PFS med 2-3 mo • OS med 12-13 mo Well known tox of neutropenia, PN, fatigue, thrombocytopenia etc. Beaten by exptl arms in StarGlo, Polargo, Sunmo Take home: no more RGemOx pls - it’s defeated! #18ICML #lymsm

Just out at Journal of Clinical Oncology: COALITION study comparing glofitamab + PolaR-CHP vs glofit-R-CHOP in frontline large B cell lymphoma - very exciting n=80 ORR 100% CRR 98% 21 month PFS 86%, OS 92% ascopubs.org/doi/10.1200/JC… Congrats Michael Dickinson Adrian Minson ! #lymsm #18ICML

David Scott’s BC Cancer algorithm for treatment of newly-diagnosed DLBCL based on recent Canadian recommendation for polatuzumab reimbursement for ABC-subtype DLBCL #lymsm #18ICML Ash Alizadeh, MD/PhD 🇺🇸

【Tigecycline: Important to know】 ID consult is needed, but please remember 5 important key points of tigecycline! Level: Intermediate to Advanced Frequency: ★★☆☆☆ #IDMedEd #IDFellow #IMResident

Wurm-Kuczera: R-pola-glo in unfit 1L DLBCL. Anthacycline ineligible ‘Ix discretion’ • glofit, pola, ritux. Fixed duration • EOT: 90% ORR & 81% CMR • 4% ICANs, G3+ CRS 2.5% V impressive responses. Need to see survival endpoints. #18ICML #ICML25 #lymsm

#18ICML LBA: DLBclass stratification of POLARIX - Cluster 5 DLBCL had superior PFS with pola-R-CHP vs R-CHOP (including in MV model) - C5: ABC-type, +BCL2, CD79Bmut, MYD88mut, extranodal #lymsm

#18ICML Big Debate: CNS prophy in DLBCL - Dr. Ferreri argues CNS relapse with v poor survival & suboptimal salvage options - He argues HD-MTX benefit outweighs toxicity, especially for high-risk EN sites - in his center experience, no CNS relapses with HD-MTX #lymsm 1/

An eye-opener review in Nature Cancer Neoadjuvant immunotherapy is transforming cancer care 🚀! ✅Now proven superior to adjuvant in trials & preclinical studies, it’s SOC in several tumors. 🔝Future focus: combos vs mono, adjuvant after neoadjuvant, & predictive biomarkers

Intermediate-Dose Cytarabine as Postinduction AML Therapy | NEJM Evidence evidence.nejm.org/doi/full/10.10…